National and Kapodistrian University of Athens
Μελέτες πυρηνικής ιατρικής στη διάγνωση και παρακολούθηση του πολλαπλού μυελώματος
Abstract
dc:descriptionAIM: The aim of the present thesis was to assess the correlation between the 99mTcSestamibi scan and prognostic factors in MM patients according to the ISS and to determine the role of the combined use of Tc-99m Sestamibi and Tc-99m (V) DMSA scans in the evaluation of the effectiveness of chemotherapy in patients with MM. METHODS: Twenty-seven patients were included in the study (females/males 14/13 mean age 62.2 ± 14.1 years). According to ISS 19 pts were at stage I, 4 stage II and 4 stage III. 18mCi Tc-99m Sestamibi and 20 mCi Tc-99m (V) DMSA were injected and whole body scans were obtained 10 min and 2 hours post injection respectively on separate days. The Tc-99m Sestamibi scans were classified according to radiopharmaceutical uptake and were scored according to intensity (I) and extent (E) of the radiotracer uptake; a summed score (S) was calculated for each patient. Scintigraphic findings were correlated with ISS, Sβ2M, and SA. The total number of Tc-99m Sestamibi and Tc-99m (V) DMSA positive lesions (TPL) was determined. Lesions that were Tc-99m (V) DMSA positive but Tc-99m Sestamibi negative were considered as partial positive lesions (PPL). The ratio of PPL/TPL was calculated and compared in patients divided in two groups regarding their clinical status: Group A (11 patients) with clinically active disease and group B (9 patients) in complete or partial remission. RESULTS: A statistically significant negative correlation between E, I and S uptake scores versus the SA levels (P=0.004, 0.049 and 0.018 respectively), as well as a statistically significant positive correlation between E and S scores and the Sβ2M levels (P=0.012 and 0.032) were detected. A statistically significant difference between the E and S uptake scores among the MM patients examined for every stage separately was also found (P=0.007 and 0.024 respectively). The gradual increase of the E and S scores across the three stages of MM was also significant but not for I score (P=0.003, 0.021 and 0.083 respectively). As for the combined use of the two scintigarphies, in group A a total of 42 Tc-99m Sestamibi positive lesions were found. Tc-99m (V) DMSA was positive in 37 of those lesions and additionally in 16 lesions which did not accumulate Tc-99m Sestamibi. Thus in group A a total of 58 MM lesions were detected and the PPL/TPL was 16/58. In group B 5 Tc-99m Sestamibi positive lesions were found. Tc-99m (V) DMSA was positive in all of those 5 lesions and additionally in 22 lesions which did not accumulate Tc-99m Sestamibi. Thus in group B a total of 27 MM lesions were detected and the PPL/TPL was 22/27. CONCLUSIONS: 1) Tc-99m Sestamibi is well correlated with Sβ2M, SA and the new International Staging System. Differences for E and S uptake scores among patients of stages I to III and evidence of increasing of these scores across the three stages were also determined providing additional evidence that 99mTc-MIBI scan reflects myeloma disease activity in bone marrow. 2) The combined use of the two agents during chemotherapy allows the evaluation of the effectiveness of the administered chemotherapy by comparing the lesions found in each study, even in the absence of a baseline study.
Degree
thesis:*- Grantor dc:publisher
- National and Kapodistrian University of Athens
- Year dc:date
- 2008
Author and committee
dc:creator, dc:contributor.*- Authors dc:creator
-
- Koutsikos, John
- Κούτσικος, Ιωάννης
Subjects
dc:subject × 11Rights
- Language dc:language
- gre
Identifiers
dc:identifier.*- Identifier
- 10.12681/eadd/22858